Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 138
Filter
1.
Lancet Infect Dis ; 22(2): 196-208, 2022 02.
Article in English | MEDLINE | ID: mdl-34536349

ABSTRACT

BACKGROUND: Although SARS-CoV-2 infection often causes milder symptoms in children and adolescents, young people might still play a key part in SARS-CoV-2 transmission. An efficacious vaccine for children and adolescents could therefore assist pandemic control. For further evaluation of the inactivated COVID-19 vaccine candidate BBIBP-CorV, we assessed the safety and immunogenicity of BBIBP-CorV in participants aged 3-17 years. METHODS: A randomised, double-blind, controlled, phase 1/2 trial was done at Shangqiu City Liangyuan District Center for Disease Control and Prevention in Henan, China. In phases 1 and 2, healthy participants were stratified according to age (3-5 years, 6-12 years, or 13-17 years) and dose group. Individuals with a history of SARS-CoV-2 or SARS-CoV infection were excluded. All participants were randomly assigned, using stratified block randomisation (block size eight), to receive three doses of 2 µg, 4 µg, or 8 µg of vaccine or control (1:1:1:1) 28 days apart. The primary outcome, safety, was analysed in the safety set, which consisted of participants who had received at least one vaccination after being randomly assigned, and had any safety evaluation information. The secondary outcomes were geometric meant titre (GMT) of the neutralising antibody against infectious SARS-CoV-2 and were analysed based on the full analysis set. This study is registered with www.chictr.org.cn, ChiCTR2000032459, and is ongoing. FINDINGS: Between Aug 14, 2020, and Sept 24, 2020, 445 participants were screened, and 288 eligible participants were randomly assigned to vaccine (n=216, 24 for each dose level [2/4/8 µg] in each of three age cohorts [3-5, 6-12, and 13-17 years]) or control (n=72, 24 for each age cohort [3-5, 6-12, and 13-17 years]) in phase 1. In phase 2, 810 participants were screened and 720 eligible participants were randomly assigned and allocated to vaccine (n=540, 60 for each dose level [2/4/8 µg] in each of three age cohorts [3-5, 6-12, and 13-17 years]) or control (n=180, 60 for each age cohort [3-5, 6-12, and 13-17 years]). The most common injection site adverse reaction was pain (ten [4%] 251 participants in all vaccination groups of the 3-5 years cohort; 23 [9·1%] of 252 participants in all vaccination groups and one [1·2%] of 84 in the control group of the 6-12 years cohort; 20 [7·9%] of 252 participants in all vaccination groups of the 13-17 years cohort). The most common systematic adverse reaction was fever (32 [12·7%] of 251 participants in all vaccination groups and six [7·1%] of 84 participants in the control group of the 3-5 years cohort; 13 [5·2%] of 252 participants in the vaccination groups and one [1·2%] of 84 in the control group of the 6-12 years cohort; 26 [10·3%] of 252 participants in all vaccination groups and eight [9·5%] of 84 in the control group of the 13-17 years cohort). Adverse reactions were mostly mild to moderate in severity. The neutralising antibody GMT against the SARS-CoV-2 virus ranged from 105·3 to 180·2 in the 3-5 years cohort, 84·1 to 168·6 in the 6-12 years cohort, and 88·0 to 155·7 in the 13-17 years cohort on day 28 after the second vaccination; and ranged from 143·5 to 224·4 in the 3-5 years cohort, 127 to 184·8 in the 6-12 years cohort, and 150·7 to 199 in the 13-17 years cohort on day 28 after the third vaccination. INTERPRETATION: The inactivated COVID-19 vaccine BBIBP-CorV is safe and well tolerated at all tested dose levels in participants aged 3-17 years. BBIBP-CorV also elicited robust humoral responses against SARS-CoV-2 infection after two doses. Our findings support the use of a 4 µg dose and two-shot regimen BBIBP-CorV in phase 3 trials in the population younger than 18 years to further ascertain its safety and protection efficacy against COVID-19. FUNDING: National Program on Key Research Project of China, National Mega projects of China for Major Infectious Diseases, National Mega Projects of China for New Drug Creation, and Beijing Science and Technology Plan. TRANSLATION: For the Chinese translation of the abstract see Supplementary Materials section.


Subject(s)
COVID-19 Vaccines/immunology , COVID-19 Vaccines/standards , COVID-19/prevention & control , Adolescent , COVID-19 Vaccines/administration & dosage , Child , Child, Preschool , Cohort Studies , Double-Blind Method , Female , Humans , Male , Vaccines, Inactivated/immunology , Vaccines, Inactivated/standards
2.
Emerg Microbes Infect ; 10(1): 1751-1759, 2021 Dec.
Article in English | MEDLINE | ID: mdl-34396940

ABSTRACT

The effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant, which has been associated with greater transmissibility and virulence, remains unclear. We conducted a test-negative case-control study to explore the vaccine effectiveness (VE) in real-world settings. We recruited participants aged 18-59 years who consisted of SARS-CoV-2 test-positive cases (n = 74) and test-negative controls (n = 292) during the outbreak of the Delta variant in May 2021 in Guangzhou city, China. Vaccination status was compared to estimate The VE of SARS-CoV-2 inactivated vaccines. A single dose of inactivated SARS-CoV-2 vaccine yielded the VE of only 13.8%. After adjusting for age and sex, the overall VE for two-dose vaccination was 59.0% (95% confidence interval: 16.0% to 81.6%) against coronavirus disease 2019 (COVID-19) and 70.2% (95% confidence interval: 29.6-89.3%) against moderate COVID-19 and 100% against severe COVID-19 which might be overestimated due to the small sample size. The VE of two-dose vaccination against COVID-19 reached 72.5% among participants aged 40-59 years, and was higher in females than in males against COVID-19 and moderate diseases. While single dose vaccination was not sufficiently protective, the two-dose dosing scheme of the inactivated vaccines was effective against the Delta variant infection in real-world settings, with the estimated efficacy exceeding the World Health Organization minimal threshold of 50%.


Subject(s)
COVID-19 Vaccines/standards , COVID-19/prevention & control , SARS-CoV-2/genetics , Adolescent , Adult , Age Distribution , COVID-19/classification , COVID-19 Vaccines/administration & dosage , Case-Control Studies , China , Disease Outbreaks , Female , Genetic Variation , Humans , Male , Middle Aged , Vaccines, Inactivated/administration & dosage , Vaccines, Inactivated/standards , Young Adult
5.
Poult Sci ; 99(9): 4334-4342, 2020 Sep.
Article in English | MEDLINE | ID: mdl-32867977

ABSTRACT

The H9N2 avian influenza virus has been widely spread in poultry around the world. It is proved to the world that the avian influenza virus can directly infect human beings without any intermediate host adaptation in "1997 Hong Kong avian influenza case," which shows that the avian influenza virus not only causes significant losses to the poultry industry but also affects human health. In this study, we aimed to address the problem of low protection of avian H9N2 subtype influenza virus vaccine against H9N2 wild-type virus. We have rescued the H9.4.2.5 branched avian influenza virus isolated in South China by reverse genetics technology. We have recombined these virus (rHA/NA-GD37 and rHA/NA-GD38) which contain hemagglutinin and neuraminidase genes from the H9N2 avian influenza virus (MN064850 or MN064851) and 6 internal genes from the avian influenza virus (KY785906). We compared the biological properties of the virus for example virus proliferation, virus elution, thermostability, and pH stability. Then, we evaluated the immune effects between rHA/NA-GD37 and GD37, which show that the recombinant avian influenza virus-inactivated vaccine can stimulate chickens to produce higher antibody titers and produce little inflammatory response after the challenge. It is noticeable that the recombinant virus-inactivated vaccine had better immune impact than the wild-type inactivated vaccine. Generally speaking, this study provides a new virus strain for the development of a H9N2 vaccine.


Subject(s)
Influenza A Virus, H9N2 Subtype , Influenza Vaccines , Influenza in Birds , Animals , Antibodies, Viral/blood , Chickens/immunology , China , Influenza A Virus, H9N2 Subtype/genetics , Influenza A Virus, H9N2 Subtype/immunology , Influenza Vaccines/immunology , Influenza Vaccines/standards , Influenza in Birds/prevention & control , Vaccines, Inactivated/immunology , Vaccines, Inactivated/standards , Vaccines, Synthetic/immunology , Vaccines, Synthetic/standards
6.
PLoS Negl Trop Dis ; 14(3): e0008142, 2020 03.
Article in English | MEDLINE | ID: mdl-32210437

ABSTRACT

Human rabies, a neglected viral zoonosis, is preventable through domestic animals vaccination and post-exposure prophylaxis using inactivated rabies vaccines. During vaccine production, several mandatory in vivo quality control trials, such as potency, live virus, and safety, are responsible for the use of large numbers of laboratory animals. Over the years, global organizations encouraged the development of alternative methods to reduce, replace and refine the use of animals in the pharmaceutical industry. In this study we standardized an in vitro assay for determination of residual live virus combining viral isolation techniques with direct immunofluorescence detection and viral quantification by a molecular method. Standardization of viral recovery steps and quantification by RT-qPCR were performed and the combined method was shown to be 3 fold more sensitive than the in vivo assay. It was possible to identify viral suspensions cultures, which still had residual viable rabies virus particles, evidencing the importance to implement this method in quality control schemes of rabies vaccine production. In addition, this developed assay is more practical, inexpensive and less time consuming, producing results in just 4 days, which may allow greater agility in the internal quality control of the vaccine. The in vitro method may reduce 2/3rd of laboratory animals numbers used for this purpose, since it can be applied in the intermediate quality control of inactivated rabies vaccine production.


Subject(s)
Rabies Vaccines/standards , Rabies virus/growth & development , Rabies virus/isolation & purification , Technology, Pharmaceutical/methods , Technology, Pharmaceutical/standards , Virus Cultivation/methods , Fluorescent Antibody Technique, Direct , Real-Time Polymerase Chain Reaction , Vaccines, Inactivated/standards
7.
Vet Microbiol ; 241: 108574, 2020 Feb.
Article in English | MEDLINE | ID: mdl-31928707

ABSTRACT

Duck circovirus (DuCV), an immunosuppressive pathogen, causes serious damage to waterfowls worldwide. A highly efficient vaccine would play a crucial role in preventing DuCV infections in the waterfowl breeding industry. However, to date, there is a dearth of commercial vaccines owing to the lack of a cell culture system for propagating the requisite virus amounts in vitro. In this study, we isolated DuCVs from Muscovy ducks, helped them proliferate using peripheral blood mononuclear cells (PBMCs), and developed an inactivated vaccine. Muscovy ducks vaccinated with the inactivated vaccine had higher neutralizing antibody titers than the control ducks and higher protection in the challenge experiment (as assessed by weight measurement). Moreover, the inactivated vaccine did not cause feather abnormalities, growth repression, and dwarf syndrome; likewise, lesions and lymphocyte apoptosis in the bursa of Fabricius, spleen, and thymus were not observed. Significantly lower virus shedding from the inactivated vaccine was detected up to 42 days post-inoculation. Together, these results suggest that the inactivated DuCV vaccine can induce a high immune response, is relatively safer for Muscovy ducks, and thus it is a protective vaccine candidates against DuCV infection.


Subject(s)
Circoviridae Infections/veterinary , Circovirus/immunology , Ducks , Poultry Diseases/prevention & control , Viral Vaccines/standards , Animals , Apoptosis , Bursa of Fabricius/pathology , Bursa of Fabricius/virology , Circoviridae Infections/prevention & control , Circovirus/genetics , Circovirus/isolation & purification , Circovirus/ultrastructure , Leukocytes, Mononuclear/pathology , Leukocytes, Mononuclear/virology , Microscopy, Electron, Transmission/veterinary , Poultry Diseases/virology , Random Allocation , Spleen/pathology , Spleen/virology , Thymus Gland/pathology , Thymus Gland/virology , Vaccines, Inactivated/standards
8.
J Virol Methods ; 270: 113-119, 2019 08.
Article in English | MEDLINE | ID: mdl-31100287

ABSTRACT

The goal of this paper was to develop a sandwich ELISA that can detect intact human enterovirus A71 (EV-A71) virus-like particles (VLPs) in vaccines. This assay specifically detected EV-A71 viruses from different sub-genogroups as well as EV-A71 VLPs, and treatment of VLPs with high heat and low pH reduced or completely abolished detection of the VLPs suggesting that the ELISA detected assembled particles. Using a purified VLP as a reference standard, a quantitative sandwich ELISA (Q-ELISA) was established which was used to monitor the yield and purity of the VLPs during manufacturing. Coupled with immunogenicity studies, the Q-ELISA was used to evaluate the performance of the VLPs and formalin-inactivated EV-A71 vaccine. This assay has the potential to play an important role in the development of an efficient process to produce and purify the VLPs and in examining the quality of EV-A71 vaccines.


Subject(s)
Enterovirus A, Human/isolation & purification , Enterovirus/isolation & purification , Enzyme-Linked Immunosorbent Assay/methods , Vaccines, Virus-Like Particle/standards , Animals , Female , Humans , Mice , Mice, Inbred BALB C , Vaccination , Vaccines, Inactivated/standards
9.
J Virol Methods ; 270: 46-51, 2019 08.
Article in English | MEDLINE | ID: mdl-31047970

ABSTRACT

Rabies is an infectious viral disease, characterized as a neglected zoonosis, responsible for nearly 60,000 deaths annually. The virus is transmitted mainly by dogs in Africa and Asia, and wildlife in Europe and the Americas, to all mammals' species, causing severe encephalitis almost always fatal after the onset of neurological symptoms. Human rabies can be prevented through extensive vaccination of dogs and pre/post-prophylaxis treatments in humans with inactivated rabies vaccines. The vaccine manufacture involves a series of quality control assays using laboratory animals, which are mandatory to exclude the presence of viable residual virus. The quality controls must be carried out in various steps during the vaccine production, which demands the use of a large number of animals. In this study, we standardized a real-time quantitative RT-PCR duplex assay to be used during intermediate stages of the vaccine production. This assay was done for the quantification of vaccine strain rabies virus, targeting rabies nucleoprotein, and ß-actin mRNA of BHK-21 cells as an internal endogenous control. The results showed specific amplification, with the analytical sensitivity ranged from 101 to 106 TCID50/mL with high repeatability rate for the quantification of rabies virus in inactivated vaccine samples. Global organizations are engaged to develop new approaches to determine viable residual virus, and this assay can be applied in combination with traditional in vitro methods for the release of intermediate batches of vaccines during the production process, keeping the in vivo tests only for final release.


Subject(s)
Rabies Vaccines/standards , Rabies virus/growth & development , Rabies virus/isolation & purification , Real-Time Polymerase Chain Reaction , Technology, Pharmaceutical/standards , Fluorescent Antibody Technique, Direct , Quality Control , Technology, Pharmaceutical/methods , Vaccines, Inactivated/standards
10.
Eur J Pharm Biopharm ; 125: 76-84, 2018 Apr.
Article in English | MEDLINE | ID: mdl-29341899

ABSTRACT

Due to their thermosensitivity, most vaccines must be kept refrigerated from production to use. To successfully carry out global immunization programs, ensuring the stability of vaccines is crucial. In this context, two important issues are critical, namely: (i) predicting vaccine stability and (ii) preventing product damage due to excessive temperature excursions outside of the recommended storage conditions (cold chain break). We applied a combination of advanced kinetics and statistical analyses on vaccine forced degradation data to accurately describe the loss of antigenicity for a multivalent freeze-dried inactivated virus vaccine containing three variants. The screening of large amounts of kinetic models combined with a statistical model selection approach resulted in the identification of two-step kinetic models. Predictions based on kinetic analysis and experimental stability data were in agreement, with approximately five percentage points difference from real values for long-term stability storage conditions, after excursions of temperature and during experimental shipments of freeze-dried products. Results showed that modeling a few months of forced degradation can be used to predict various time and temperature profiles endured by vaccines, i.e. long-term stability, short time excursions outside the labeled storage conditions or shipments at ambient temperature, with high accuracy. Pharmaceutical applications of the presented kinetics-based approach are discussed.


Subject(s)
Vaccine Potency , Vaccines, Inactivated/standards , Drug Stability , Drug Storage/methods , Drug Storage/standards , Forecasting , Freeze Drying/methods , Freeze Drying/standards , Temperature , Time Factors , Vaccines, Inactivated/chemistry
11.
Biologicals ; 50: 100-108, 2017 Nov.
Article in English | MEDLINE | ID: mdl-28838806

ABSTRACT

The leukopenic toxicity test (LTT) is used to evaluate the safety and lot-to-lot consistency of influenza hemagglutinin split vaccine (HAv) and is included in the Japanese Minimum Requirements for Biological Products. LTT assesses the reduced leukocyte levels in murine peripheral blood after HAv administration. However, they require large numbers of animals, and therefore it would be beneficial to develop a more accurate and sensitive alternative method. In this study, we selected biomarkers of leukocyte reduction from 18 previously identified marker genes that were associated with an abnormal toxicity test (ATT). Among these 18 genes, the expressions of 15 marker genes were strongly associated with leukocyte reduction levels. A stepwise single addition multiple regression analysis was used to further extract the genes responsible for leukocyte reduction, with significant (p < 0.25) regression coefficients. The expression of 7 genes significantly predicted the leukocyte reduction. The prediction accuracy of this approach was approximately >90% (mean) for the direct measurement of leukocyte numbers. These results indicate that the expression of these 18 previously identified genes can provide information for both ATT and LTT.


Subject(s)
Cytotoxicity Tests, Immunologic/methods , Influenza Vaccines/immunology , Leukocytes/immunology , Vaccines, Inactivated/immunology , Animals , Biomarkers/metabolism , Female , Gene Expression Profiling/methods , Influenza A Virus, H1N1 Subtype/immunology , Influenza A Virus, H3N2 Subtype/immunology , Influenza Vaccines/pharmacology , Influenza Vaccines/standards , Leukocyte Count , Leukocytes/drug effects , Leukocytes/metabolism , Lung/immunology , Lung/metabolism , Lung/virology , Mice, Inbred BALB C , Orthomyxoviridae Infections/genetics , Orthomyxoviridae Infections/immunology , Orthomyxoviridae Infections/virology , Vaccination , Vaccines, Inactivated/pharmacology , Vaccines, Inactivated/standards
12.
Vet Microbiol ; 199: 47-53, 2017 Feb.
Article in English | MEDLINE | ID: mdl-28110784

ABSTRACT

Originally isolated from swine, the proposed influenza D virus has since been shown to be common in cattle. Inoculation of IDV to naïve calves resulted in mild respiratory disease histologically characterized by tracheitis. As several studies have associated the presence of IDV with acute bovine respiratory disease (BRD), we sought to investigate the efficacy of an inactivated IDV vaccine. Vaccinated calves seroconverted with hemagglutination inhibition titers 137-169 following two doses. Non-vaccinated calves challenged with a homologous virus exhibited signs of mild respiratory disease from days four to ten post challenge which was significantly different than negative controls at days five and nine post challenge. Peak viral shedding of approximately 5 TCID50/mL was measured in nasal and tracheal swabs and bronchoalveolar lavage fluids four to six days post challenge. Viral titers were significantly (P<0.05) decreased 1.4 TCID50/mL, 3.6 TCID50/mL and 5.0 TCID50/mL, respectively, in the aforementioned samples collected from vaccinated animals compared to non-vaccinated controls at peak shedding. Viral antigen was detected in the respiratory epithelium of the nasal turbinates and trachea by immunohistochemistry from all unvaccinated calves but in significantly fewer vaccinates. Inflammation characterized by neutrophils was observed in the nasal turbinate and trachea but not appreciably in lungs. Together these results support an etiologic role for IDV in BRD and demonstrate that partial protection is afforded by an inactivated vaccine.


Subject(s)
Bovine Respiratory Disease Complex/immunology , Cattle Diseases/immunology , Cattle Diseases/virology , Orthomyxoviridae Infections/veterinary , Thogotovirus/immunology , Viral Vaccines/immunology , Animals , Antibodies, Viral/blood , Antigens, Viral/isolation & purification , Bovine Respiratory Disease Complex/pathology , Bovine Respiratory Disease Complex/prevention & control , Bovine Respiratory Disease Complex/virology , Cattle , Cattle Diseases/prevention & control , Orthomyxoviridae Infections/immunology , Orthomyxoviridae Infections/virology , Vaccination , Vaccines, Inactivated/immunology , Vaccines, Inactivated/standards , Viral Load , Viral Vaccines/standards , Virus Shedding
13.
BMC Vet Res ; 12(1): 277, 2016 Dec 07.
Article in English | MEDLINE | ID: mdl-27923365

ABSTRACT

BACKGROUND: Since the end of 2011 an outbreak of pseudorabies affected Chinese pig herds that had been vaccinated with the commercial vaccine made of Bartha K61 strain. It is now clear that the outbreak was caused by an emergent PRV variant. Even though vaccines made of PRV Bartha K61 strain can confer certain cross protection against PRV variants based on experimental data, less than optimal clinical protection and virus shedding reduction were observed, making the control or eradication of this disease difficult. RESULTS: An infectious clone of PRV AH02LA strain was constructed to generate a gE deletion mutant PRV(LA-AB) strain. PRV(LA-AB) strain can reach a titer of 108.43 TCID50 /mL (50% tissue culture infectious dose) on BHK-21 cells. To evaluate the efficiency of the inactivated vaccine made of PRV(LA-AB) strain, thirty 3-week-old PRV-negative piglets were divided randomly into six groups for vaccination and challenge test. All five piglets in the challenge control showed typical clinical symptoms of pseudorabies post challenge. Sneezing and nasal discharge were observed in four and three piglets in groups C(vaccinated with inactivated PRV Bartha K61 strain vaccine) and D(vaccinated with live PRV Bartha K61 strain vaccine) respectively. In contrast, piglets in both groups A(vaccinated with inactivated PRV LA-AB strain vaccine) and B(vaccinated with inactivated PRV LA-AB strain vaccine with adjuvant) presented mild or no clinical symptoms. Moreover, viral titers detected via nasal swabs were approximately 100 times lower in group B than in the challenge control, and the duration of virus shedding (3-4 days) was shorter than in either the challenge control (5-10 days) or groups C and D (5-6 days). CONCLUSIONS: The infectious clone constructed in this study harbors the whole genome of the PRV variant AH02LA strain. The gE deletion mutant PRV(LA-AB)strain generated from PRV AH02LA strain can reach a high titer on BHK-21 cells. An inactivated vaccine of PRV LA-AB provides clinical protection and significantly reduces virus shedding post challenge, especially if accompanied by the adjuvant CVC1302. While Inactivated or live vaccines made of PRV Barth K61 strain can provide only partial protection in this test.


Subject(s)
Pseudorabies Vaccines/standards , Pseudorabies/prevention & control , Swine Diseases/prevention & control , Viral Vaccines/standards , Virus Shedding/immunology , Animals , China , Gene Deletion , Herpesviridae/genetics , Herpesviridae/immunology , Nose/virology , Pseudorabies/pathology , Pseudorabies/virology , Pseudorabies Vaccines/immunology , Random Allocation , Swine , Swine Diseases/pathology , Swine Diseases/virology , Vaccines, Inactivated/immunology , Vaccines, Inactivated/standards , Viral Envelope Proteins/genetics , Viral Envelope Proteins/immunology , Viral Vaccines/immunology
14.
J Infect ; 72 Suppl: S13-22, 2016 07 05.
Article in English | MEDLINE | ID: mdl-27233121

ABSTRACT

Immunocompromised children have a higher risk of developing infections and associated higher rates of mortality and morbidity. Although this group could benefit the most from vaccine administration, specific considerations regarding immunisations are required. This review is a summary of the vaccines that are relevant to the immunocompromised host, covering both live and non-live vaccines. The burden of disease, safety, immunogenicity/effectiveness and specific recommendations for each vaccine are described as well as specific guidelines from different organisations.


Subject(s)
Immunocompromised Host , Vaccines/adverse effects , Vaccines/immunology , Child , Humans , Immunization/methods , Immunization/standards , Immunogenicity, Vaccine , Infant , Practice Guidelines as Topic , Vaccines/administration & dosage , Vaccines, Inactivated/administration & dosage , Vaccines, Inactivated/adverse effects , Vaccines, Inactivated/immunology , Vaccines, Inactivated/standards , Vaccines, Live, Unattenuated/administration & dosage , Vaccines, Live, Unattenuated/adverse effects , Vaccines, Live, Unattenuated/immunology , Vaccines, Live, Unattenuated/standards
15.
Biologicals ; 44(4): 198-205, 2016 Jul.
Article in English | MEDLINE | ID: mdl-27068366

ABSTRACT

A reference standard calibrated in the International Units is needed for the quality control of hepatitis A vaccine. Thus, National Institutes for Food and Drug Control launched a project to establish a non-adsorbed inactivated hepatitis A vaccine reference as the working standard calibrated against the 1st International Standard (IS). Two national standard candidates (NSCs) were obtained from two manufacturers, and designated as NSC A (lyophilized form) and NSC B (liquid form). Six laboratories participated in the collaborative study and were asked to use their in-house validated enzyme-linked immunosorbent assay methods to detect hepatitis A vaccine antigen content. Although both exhibited good parallelism and linear relationship with IS, NSC B showed a better agreement among laboratories than NSC A. And based on suitability of the candidates, NSC B was selected. The accelerated degradation study showed that NSC B was stable at the storage temperature (≤-70 °C). Therefore NSC B was approved as the first Chinese national antigen standard for inactivated hepatitis A vaccine, with an assigned antigen content of 70 IU/ml.


Subject(s)
Hepatitis A Antigens/immunology , Hepatitis A Vaccines/immunology , Hepatitis A Vaccines/standards , Calibration , China , Drug Stability , Drug Storage/methods , Enzyme-Linked Immunosorbent Assay , Freeze Drying , Freezing , Humans , International Cooperation , Laboratories/standards , Quality Control , Reference Standards , Vaccines, Inactivated/immunology , Vaccines, Inactivated/standards
16.
J Am Vet Med Assoc ; 248(9): 1043-9, 2016 May 01.
Article in English | MEDLINE | ID: mdl-27074613

ABSTRACT

OBJECTIVE To compare the humoral response between sheep vaccinated with a killed-virus (KV) vaccine and those vaccinated with a modified-live virus (MLV) vaccine against bluetongue virus (BTV) serotype 17. DESIGN Randomized clinical trial followed by a field trial. ANIMALS 30 yearling crossbred ewes (phase 1) and 344 sheep from 7 Wyoming farms (phase 2). PROCEDURES In phase 1, ewes seronegative for anti-BTV antibodies received sterile diluent (control group; n = 10) or an MLV (10) or KV (10) vaccine against BTV-17 on day 0. Ewes in the KV group received a second dose of the vaccine on day 21. Ewes were bred 5 months after vaccination and allowed to lamb. Anti-BTV antibodies were measured in ewes at predetermined times after vaccination and in their lambs once at 5 to 10 days after birth. In phase 2, 248 commercial sheep were screened for anti-BTV antibodies and vaccinated with a KV vaccine against BTV-17 on day 0. Sheep seronegative for anti-BTV antibodies on day 0 (n = 90) underwent follow-up serologic testing on day 365 along with 96 unvaccinated cohorts (controls). RESULTS In phase 1, all vaccinated ewes developed anti-BTV antibodies by 14 days after vaccination and remained seropositive for 1 year; all of their lambs were also seropositive. All control ewes and lambs were seronegative. In phase 2, the prevalence of vaccinated sheep with anti-BTV antibodies 1 year after vaccination was 93% and 76% as determined by a serum neutralization assay and competitive ELISA, respectively. CONCLUSIONS AND CLINICAL RELEVANCE Both vaccines induced antibodies against BTV-17 that persisted for at least 1 year and provided passive immunity for lambs and may be a viable option to protect sheep against disease.


Subject(s)
Bluetongue virus/immunology , Bluetongue/prevention & control , Sheep/immunology , Vaccines, Attenuated/immunology , Vaccines, Inactivated/immunology , Viral Vaccines/immunology , Animals , Antibodies, Viral/biosynthesis , Antibodies, Viral/blood , Bluetongue/immunology , Female , Immunity, Maternally-Acquired , Kinetics , Male , Prospective Studies , Vaccines, Attenuated/standards , Vaccines, Inactivated/standards , Viral Vaccines/classification , Viral Vaccines/standards
17.
Influenza Other Respir Viruses ; 10(2): 134-40, 2016 Mar.
Article in English | MEDLINE | ID: mdl-26616263

ABSTRACT

BACKGROUND: The potency of inactivated influenza vaccines is determined using a single-radial immunodiffusion (SRID) assay and requires standardized reagents consisting of a Reference Antigen and an influenza strain-specific antiserum. Timely availability of reagents is a critical step in influenza vaccine production, and the need for backup approaches for reagent preparation is an important component of pandemic preparedness. OBJECTIVES: When novel H7N9 viruses emerged in China in 2013, candidate inactivated H7N9 influenza vaccines were developed for evaluation in clinical trials, and reagents were needed to measure vaccine potency. METHODS: We previously described an alternative approach for generating strain-specific potency antisera, utilizing modified vaccinia virus Ankara vectors to produce influenza hemagglutinin (HA)-containing virus-like particles (VLPs) for immunization. Vector-produced HA antigen is not dependent upon the success of the traditional bromelain-digestion and HA purification. RESULTS: Antiserum for H7N9 vaccines, produced after immunization of sheep with preparations of bromelain-HA (br-HA), was not optimal for the SRID assay, and the supply of antiserum was limited. However, antiserum obtained from sheep boosted with VLPs containing H7 HA greatly improved the ring quality in the SRID assay. Importantly, this antiserum worked well with both egg- and cell-derived antigen and was distributed to vaccine manufacturers. CONCLUSIONS: Utilizing a previously developed approach for preparing vaccine potency antiserum, we have addressed a major bottleneck encountered in preparation of H7N9 vaccine reagents. The combination of br-HA and mammalian VLPs for sequential immunization represents the first use of an alternative approach for producing an influenza vaccine potency antiserum.


Subject(s)
Antibodies, Viral/biosynthesis , Immune Sera/biosynthesis , Influenza A Virus, H7N9 Subtype/immunology , Influenza Vaccines/immunology , Vaccine Potency , Vaccines, Inactivated/immunology , Animals , China , Hemagglutinin Glycoproteins, Influenza Virus/immunology , Humans , Immunodiffusion , Influenza A Virus, H1N1 Subtype/immunology , Influenza A Virus, H5N1 Subtype/immunology , Influenza A Virus, H7N9 Subtype/growth & development , Influenza Vaccines/standards , Influenza, Human/prevention & control , Influenza, Human/virology , Pandemics/prevention & control , Sheep , Vaccines, Inactivated/standards , Vaccines, Virus-Like Particle/immunology
18.
Vet Parasitol ; 214(3-4): 247-54, 2015 Dec 15.
Article in English | MEDLINE | ID: mdl-26553499

ABSTRACT

The aim of the present study was to investigate and correlate the cell-mediated immune response and pathological changes at the maternal-fetal interface of Neospora-challenged pregnant cattle previously immunized with live and inactivated experimental vaccines. Pregnant heifers naïve to Neospora caninum were divided in 5 groups of 4 animals, each one immunized before mating: Group A heifers were intravenously (iv) immunized with 6.25 × 10(7) live tachyzoites of the NC-6 strain; group B heifers were immunized twice subcutaneously (sc) 3 weeks apart with native antigen extract of the NC-6 strain formulated with ISCOMs; group C heifers were sc immunized twice 3 weeks apart with three recombinant proteins (rNcSAG1, rNcHSP20, rNcGRA7) of the NC-1 strain formulated with ISCOMs; group D heifers were sc injected with sterile phosphate-buffered saline (PBS) and group E heifers received sc ISCOM-matrix (ISCOMs without antigen). All groups were iv-challenged with 4.7 × 10(7) NC-1 tachyzoites at 70 days of gestation. Heifers were culled at day 104 of gestation and placentomes were examined to evaluate lesions and local cellular immune responses using histopathology, immunohistochemistry and real time-PCR. Immunohistochemistry was performed using bovine leucocyte specific antibodies. Cytokine expression and levels (IFN-γ, IL-4, IL-10, IL-12 and TNF-α) were measured using real-time reverse transcription-PCR and ELISA, respectively. Minimal inflammation was observed in group A placentomes; while placentomes from group B, C, D and E had moderate to severe infiltration with CD3(+), CD4(+), γδ-T cells, CD8(+) cells and macrophages being more numerous in groups B and E placentomes, when compared with groups C and D (P<0.001). Cytokine levels were significantly increased in the caruncles of animals of groups B and C in comparison with the other animal groups (P < 0.001). The results from this study showed that the strongest cellular immune responses were observed in the placentomes of animals that were immunized with inactivated vaccines (groups B and C) and in the placentomes of animals that were sc-sham-inoculated (groups D and E). On the other hand, animals that were immunized with live tachyzoites showed a milder immune cell infiltration to the placenta possibly due to the existence of a protective systemic maternal immune response that helped to minimize N. caninum infection at the maternal-fetal interface.


Subject(s)
Cattle Diseases/immunology , Coccidiosis/veterinary , Immunity, Cellular/immunology , Neospora/immunology , Placenta/immunology , Protozoan Vaccines/immunology , Animals , Cattle , Cattle Diseases/prevention & control , Coccidiosis/immunology , Cytokines/blood , Female , Pregnancy , Protozoan Vaccines/standards , Vaccination/veterinary , Vaccines, Inactivated/immunology , Vaccines, Inactivated/standards
19.
J Pediatric Infect Dis Soc ; 4(3): 214-24, 2015 Sep.
Article in English | MEDLINE | ID: mdl-26334249

ABSTRACT

BACKGROUND: Children 6 through 35 months of age are recommended to receive half the dose of influenza vaccine compared with older children and adults. METHODS: This was a 6-site, randomized 2:1, double-blind study comparing full-dose (0.5 mL) trivalent inactivated influenza vaccine (TIV) with half-dose (0.25 mL) TIV in children 6 through 35 months of age. Children previously immunized with influenza vaccine (primed cohort) received 1 dose, and those with no previous influenza immunizations (naive cohort) received 2 doses of TIV. Local and systemic adverse events were recorded. Sera were collected before immunization and 1 month after last dose of TIV. Hemagglutination inhibition antibody testing was performed. RESULTS: Of the 243 subjects enrolled (32 primed, 211 naive), data for 232 were available for complete analysis. No significant differences in local or systemic reactions were observed. Few significant differences in immunogenicity to the 3 vaccine antigens were noted. The immune response to H1N1 was significantly higher in the full-dose group among primed subjects. In the naive cohort, the geometric mean titer for all 3 antigens after 2 doses of TIV were significantly higher in the 12 through 35 months compared with the 6 through 11 months age group. CONCLUSIONS: Our study confirms the safety of full-dose TIV given to children 6 through 35 months of age. An increase in antibody responses after full- versus half-dose TIV was not observed, except for H1N1 in the primed group. Larger studies are needed to clarify the potential for improved immunogenicity with higher vaccine doses. Recommending the same dose could simplify the production, storage, and administration of influenza vaccines.


Subject(s)
Immunogenicity, Vaccine , Influenza Vaccines/administration & dosage , Influenza Vaccines/standards , Vaccines, Inactivated/administration & dosage , Vaccines, Inactivated/standards , Child, Preschool , Double-Blind Method , Female , Hemagglutination Inhibition Tests , Humans , Infant , Influenza A Virus, H1N1 Subtype/immunology , Influenza Vaccines/adverse effects , Influenza, Human/prevention & control , Male , Vaccines, Inactivated/adverse effects
20.
Vaccine ; 33(32): 3843-9, 2015 Jul 31.
Article in English | MEDLINE | ID: mdl-26144898

ABSTRACT

Regulatory potency test for rabies vaccines requires mice vaccination followed by challenge with a live virus via intracerebral route. An alternative in vitro test, consistent with the "3R's" (Reduce, Replace, Refine) was designed to quantify active glycoprotein G using seroneutralizing monoclonal antibodies. This versatile ELISA targets well conformed neutralizing epitopes. Therefore, it quantifies only the trimeric pre-fusion form of glycoprotein G known to elicits the production of viral neutralizing antibodies. The ELISA makes it possible to quantify the rabies antigen during all steps of the product cycle (i.e. viral cultivation, downstream process, formulation and product stability in the presence of aluminum gel or other vaccine valence). Moreover, the batch-to-batch consistency of our active ingredients and formulated products could be demonstrated.


Subject(s)
Antigens, Viral/analysis , Enzyme-Linked Immunosorbent Assay/methods , Rabies Vaccines/immunology , Technology, Pharmaceutical/methods , Vaccine Potency , Veterinary Medicine/methods , Animals , Mice, Inbred BALB C , Rabies Vaccines/standards , Technology, Pharmaceutical/standards , Vaccines, Inactivated/immunology , Vaccines, Inactivated/standards , Veterinary Medicine/standards
SELECTION OF CITATIONS
SEARCH DETAIL
...